Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc.

CRL

NYSEHealthcareMedical - Diagnostics & Research

Previous close

$295.19

+$3.74 · +1.28%

Aug 21, 4:00 PM ET

CRL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

5

Overpriced

Momentum

68

Gaining

Sentiment

65

Bullish

Risk resilience

61

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Birgit Girshick
Listed since
Jun 23, 2000
Employees
19,000

Market position

Day range

Current $295.19

52-week range

Current $295.19

Open
$290.33
Previous close
$291.45
Volume
757.76K
0.85× average
Average volume
896.34K
Average daily volume
Market cap
14.22B USD
Beta
1.38
Market reference 1
50-day average
$234.14
+26.07% above average
200-day average
$194.02
+52.14% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
12.95B USD
P/E (TTM)
-60.99×
P/B (TTM)
5.04×
P/S (TTM)
3.56×
EV / EBITDA
31.51×
Earnings yield
-1.43%
Free cash flow yield
5.14%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
32.24%
Operating margin
12.35%
Net margin
-5.96%
Return on equity
-4.56%
Return on assets
-2.02%
Return on invested capital
8.36%

Financial health

Debt / equity
1.07×
Current ratio
1.29×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends42%25%9%-8%Gross margin, FY2021: 37.70%Gross margin, FY2022: 36.79%Gross margin, FY2023: 36.39%Gross margin, FY2024: 32.88%Gross margin, FY2025: 30.52%Operating margin, FY2021: 16.66%Operating margin, FY2022: 16.37%Operating margin, FY2023: 14.95%Operating margin, FY2024: 5.61%Operating margin, FY2025: 12.65%Net margin, FY2021: 11.04%Net margin, FY2022: 12.23%Net margin, FY2023: 11.49%Net margin, FY2024: 0.25%Net margin, FY2025: -3.59%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 37.70%. Gross margin FY2022 36.79%. Gross margin FY2023 36.39%. Gross margin FY2024 32.88%. Gross margin FY2025 30.52%. Operating margin FY2021 16.66%. Operating margin FY2022 16.37%. Operating margin FY2023 14.95%. Operating margin FY2024 5.61%. Operating margin FY2025 12.65%. Net margin FY2021 11.04%. Net margin FY2022 12.23%. Net margin FY2023 11.49%. Net margin FY2024 0.25%. Net margin FY2025 -3.59%.

Income trends

Revenue

4.02B USD-0.85%

Operating income

507.84M USD+123.38%

Net income

−144.34M USD−154.64M USD
Income trends across reported periods4.56B USD2.85B USD1.14B USD−571.71M USDRevenue, FY2021: 3.54B USDRevenue, FY2022: 3.98B USDRevenue, FY2023: 4.13B USDRevenue, FY2024: 4.05B USDRevenue, FY2025: 4.02B USDOperating income, FY2021: 589.86M USDOperating income, FY2022: 650.98M USDOperating income, FY2023: 617.26M USDOperating income, FY2024: 227.35M USDOperating income, FY2025: 507.84M USDNet income, FY2021: 390.98M USDNet income, FY2022: 486.23M USDNet income, FY2023: 474.62M USDNet income, FY2024: 10.3M USDNet income, FY2025: −144.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.54B USD. Revenue FY2022 3.98B USD. Revenue FY2023 4.13B USD. Revenue FY2024 4.05B USD. Revenue FY2025 4.02B USD. Operating income FY2021 589.86M USD. Operating income FY2022 650.98M USD. Operating income FY2023 617.26M USD. Operating income FY2024 227.35M USD. Operating income FY2025 507.84M USD. Net income FY2021 390.98M USD. Net income FY2022 486.23M USD. Net income FY2023 474.62M USD. Net income FY2024 10.3M USD. Net income FY2025 −144.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.02B USD4.05B USD4.13B USD3.98B USD3.54B USD
Cost of goods sold2.79B USD2.72B USD2.63B USD2.51B USD2.21B USD
Gross profit1.23B USD1.33B USD1.5B USD1.46B USD1.33B USD
Selling, general, and administrative743.07M USD751M USD747.86M USD665.1M USD619.92M USD
Operating expenses717.73M USD1.1B USD885.3M USD811.68M USD744.78M USD
Interest income4.94M USD8.58M USD5.2M USD780K USD652K USD
Interest expense107.03M USD126.29M USD136.71M USD59.29M USD73.91M USD
Depreciation and amortization403.31M USD361.74M USD314.12M USD303.87M USD265.54M USD
Operating income507.84M USD227.35M USD617.26M USD650.98M USD589.86M USD
Net income−144.34M USD10.3M USD474.62M USD486.23M USD390.98M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+9.52%
11 comparable reports
Latest EPS result
3.02
Estimate 2.74 · Beat by 10.22%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates3.242.772.311.84Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual 2.66, estimate 2.5, surprise +6.40%, Beat. Q2 2025, reported May 7, 2025: actual 2.34, estimate 2.06, surprise +13.59%, Beat. Q3 2025, reported Aug 6, 2025: actual 3.12, estimate 2.5, surprise +24.80%, Beat. Q4 2025, reported Nov 5, 2025: actual 2.43, estimate 2.32, surprise +4.74%, Beat. Q1 2026, reported Feb 18, 2026: actual 2.39, estimate 2.33, surprise +2.58%, Beat. Q2 2026, reported May 7, 2026: actual 2.06, estimate 1.96, surprise +5.10%, Beat. Q3 2026, reported Aug 5, 2026: actual 3.02, estimate 2.74, surprise +10.22%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 2.97, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.07B1.02B962.43M906.94MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual 1B USD, estimate 948.22M USD, surprise +5.73%, Beat. Q2 2025, reported May 7, 2025: actual 984.17M USD, estimate 958.79M USD, surprise +2.65%, Beat. Q3 2025, reported Aug 6, 2025: actual 1.03B USD, estimate 968.92M USD, surprise +6.52%, Beat. Q4 2025, reported Nov 5, 2025: actual 1B USD, estimate 987.2M USD, surprise +1.79%, Beat. Q1 2026, reported Feb 18, 2026: actual 994.23M USD, estimate 987.02M USD, surprise +0.73%, Beat. Q2 2026, reported May 7, 2026: actual 995.83M USD, estimate 977.46M USD, surprise +1.88%, Beat. Q3 2026, reported Aug 5, 2026: actual 1B USD, estimate 977.2M USD, surprise +2.75%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 958.47M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$267.6

9.35% downside
Past 12 months12-month forecastHigh $300Average $267.6Low $219

CRL news

CRL peers

ETFs holding CRL

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research CRL

research.disclaimer